


Exhibit A

UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450

Serial Number	Filing Date	First Named Applicant	Attorney Docket No.
10/091,714	3/5/2002	Mansuy et al.	64481/JPW/AJM/BJA



EXAMINER	
Anne-Marie Falk, Ph.D.	
ART UNIT	PAPER NUMBER
1632	0106

Please find below a communication from the EXAMINER in charge of this application

30 days / 1 month response due: 2/11/06 (4144)
Commissioner of Patents

The reply filed on October 7, 2005 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s):

The amendment format does not comply with the requirements of 37 CFR 1.121. Amended claims must include appropriate markings to show the changes that have been made relative to the immediate prior version of the claims. However, the markings for Claim 4 are not consistent with the prior version of the claim. The term "AI" appears to have been newly inserted into the claim without underlining to show the amendment. Appropriate correction is required. See 37 CFR 1.121(c).

Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a)**. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne-Marie Falk, Ph.D. whose telephone number is (571) 272-0728. The examiner can normally be reached Monday through Friday from 10:30 AM to 7:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571) 272-0735. The central official fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Anne-Marie Falk, Ph.D.

Anne-Marie Falk
ANNE-MARIE FALK, PH.D.
PRIMARY EXAMINER

Resp. rem. 1/23/06 ?
due 2/10/06 3781
JPM

BTA

Applicants: Isabelle Mansuy et al.
U.S. Serial No.: 10/091,714
Filed: March 2, 2002
Exhibit A



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/091,714	03/05/2002	Isabelle Mansuy	64481/JPW/AJM/MML	7463
7590 01/11/2006				
Cooper & Dunham, LLP 1185 Avenue of the Americas New York, NY 10036		EXAMINER FALK, ANNE MARIE		
		ART UNIT 1632		PAPER NUMBER
DATE MAILED: 01/11/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

Exhibit B

Listing of Claims:

1. (Currently Amended) A transgenic nonhuman mammal whose germ ~~or~~ and somatic cells contain (i) a first heterologous nucleic acid sequence encoding a transcriptional activator whose expression is under the control of a CaMKII α promoter and (ii) a second heterologous nucleic acid sequence encoding a calcineurin inhibitor protein whose expression is under the control of a promoter responsive to the transcriptional activator in a regulatable manner, wherein the mammal exhibits enhanced calcineurin inhibitor protein expression on induction of the transcriptional activator.
2. (Original) The transgenic nonhuman mammal of claim 1, wherein the transcriptional activator comprises rtTA and the promoter of the second nucleic acid sequence comprises a tetracycline-responsive sequence.
3. (Canceled).
4. (Currently Amended) The transgenic nonhuman mammal of claim 1 3, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.
5. (Currently Amended) The transgenic nonhuman mammal of claim 1 3, wherein the expression of the calcineurin inhibitor protein is induced by doxycycline.
6. (Original) The transgenic nonhuman mammal of claim 1, wherein the transcriptional activator comprises tTA and the

promoter of the second nucleic acid sequence comprises a tetracycline-responsive sequence.

7. (Canceled).
8. (Currently Amended) The transgenic nonhuman mammal of claim 7 6, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.
9. (Currently Amended) The transgenic nonhuman mammal of claim 7 6, wherein the expression of the calcineurin inhibitor protein is repressed by doxycycline.
10. (Original) The transgenic nonhuman mammal of claim 1, wherein the mammal is selected from the group consisting of a mouse, a rat, a sheep, a cow, a dog, a pig, and a primate.
- 11-20. (Canceled)
21. (Currently Amended) A nonhuman composition of matter comprising (i) a first nucleic acid encoding a transcriptional activator whose expression is under the control of a CaMKII α promoter and (ii) a second nucleic acid encoding a calcineurin inhibitor protein whose expression is under the control of a promoter responsive to the transcriptional activator in a regulatable manner, wherein the nonhuman composition of matter exhibits enhanced calcineurin inhibitor protein expression on induction of the transcriptional activator.

22. (Original) The composition of matter of claim 21, wherein the first and second nucleic acids exist in the same nucleic acid molecule.
23. (Original) The composition of matter of claim 21, wherein the transcriptional activator comprises rtTA and the promoter of the second nucleic acid sequence comprises a tetracycline-responsive sequence.
24. (Canceled).
25. (Currently Amended) The composition of matter of claim ~~24~~ 21, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.
26. (Currently Amended) The composition of matter of claim ~~24~~ 21, wherein the expression of the calcineurin inhibitor protein is induced by doxycycline.
27. (Original) The composition of matter of claim 21, wherein the transcriptional activator comprises tTA and the promoter of the second nucleic acid sequence comprises a tetracycline-responsive sequence.
28. (Canceled).
29. (Currently Amended) The composition of matter of claim ~~28~~ 21, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.
30. (Currently Amended) The composition of matter of claim ~~28~~ 21, wherein the expression of the calcineurin inhibitor protein is repressed by doxycycline.

Applicant: Isabelle Mansuy and Eric R. Kandel
U.S. Serial No.: 10/091,714
Filed: March 5, 2002
Page 6

31-34. (Canceled)